Literature DB >> 15627879

Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient.

Gavin R Graff1, James M Stark, Ryan Grueber.   

Abstract

Dyspnea, the subjective symptom feeling of breathlessness, is a common symptom in terminally ill patients with cystic fibrosis (CF). The palliation of the dyspnea is a reasonable goal to improve patient comfort as the progression of the disease worsens. We report the successful use of inhaled fentanyl for 3 days in a 17-year-old female with terminal CF lung disease, as measured by improved oxygenation and a reduction in the modified Borg score, and the subjective feeling of less air hunger reported by parents and patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15627879     DOI: 10.1159/000081769

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  3 in total

1.  Palliative drug treatments for breathlessness in cystic fibrosis.

Authors:  Nishant Jaiswal; Meenu Singh; Amit Agarwal; Anil Chauhan; Nikita Jaiswal
Journal:  Cochrane Database Syst Rev       Date:  2020-04-28

Review 2.  Palliative drug treatments for breathlessness in cystic fibrosis.

Authors:  Nishant Jaiswal; Meenu Singh; Amit Agarwal; Kiran K Thumburu
Journal:  Cochrane Database Syst Rev       Date:  2017-08-10

3.  Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions.

Authors:  Lucas Pieper; Julia Wager; Boris Zernikow
Journal:  BMC Palliat Care       Date:  2018-09-10       Impact factor: 3.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.